Compare Recursion Pharmaceuticals Inc (RXRX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Parcel Service Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while United Parcel Service Inc trades at $104.44 (market cap $89.09B). The key difference: United Parcel Service Inc is far larger — about 50.1× Recursion Pharmaceuticals Inc's market cap, and United Parcel Service Inc pays a 6.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | UPS | |
|---|---|---|
Market Cap | $1.78B | $89.09B |
Sector | Health | Industrials |
52-Week High | $6.79 | $120.00 |
52-Week Low | $2.84 | $82.58 |
Enterprise Value | $1.30B | $113.11B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
UPS trades at $104.48, up 1.24% daily, with a bearish technical signal but recent earnings beats. Revenue declined to $88.66B in 2025, with net income margin at 5.08%, while valuation ratios like P/E of 19.42 and P/S of 0.99 suggest moderate pricing. The company maintains a strong dividend yield, with recent payouts of $1.64 per share, and analyst consensus is mixed amid cost-cutting efforts and Amazon volume reset.
Outlook is cautious due to margin pressures and competitive threats, but upside exists if operational efficiencies materialize. Risks include high debt-to-asset ratio of 33.02% and volatile cash flows. Analysts target $117.90 on average, implying potential growth, but investor sentiment remains divided given bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
